Bhavesh Pranav’s mission is to help people survive some of the deadliest cancers through one simple yet curative step—a blood test to identify cancer early. His pursuit originates from a frustration with the sometimes misaligned incentives in healthcare. As co-founder of Phylomics, he aspires to demonstrate the economic benefits of early detection for patients, payers, and physicians.

Bhavesh is a recent MBA graduate from Southern Methodist University in Dallas, Texas. He won the 2017 SMU business plan competition, was a finalist at Princeton TigerLauch and the Stu Clarke investment competition in Canada. Prior to SMU, Bhavesh earned a dual master’s in Biophysics and Physiology at Georgetown University and completed his master’s practicum and fellowship at Yale University.

Venture: Phylomics produces an innovative blood test used by doctors to detect multiple types of cancers in asymptomatic patients. By producing a cancer screening used as part of an annual physical, Phylomics detects cancer early—when treatment is most effective. Phylomics’ analysis is highly predictive and can detect a growing number of cancers including breast, prostate, pancreatic, lung, ovarian, and colorectal.